Khalid Islam - Mar 31, 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Director
Signature
/s/ Khalid Islam by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Mar 31, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 05:57 PM
Previous filing
Apr 19, 2022
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Award +4.39K +6.45% 72.5K Mar 31, 2022 Direct F1, F2
holding PCSA Common Stock 121K Mar 31, 2022 by Elion Oncology, Inc. F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting of time-based restricted shares.
F2 Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in a transaction exempt from Section 16 reporting pursuant to Rule 16a-13.